Ultragenyx Pharmaceutical (RARE) shares were down 50% in premarket activity Thursday after the company said overnight that its phase 3 Aspire study of apazunersen in Angelman syndrome - a rare neurogenetic disorder - failed to meet the primary endpoint and a key secondary endpoint.

Research Alliance (RACC) stock was 21% lower, extending the 3.7% fall in the previous session.

Victoria's Secret (VSXY) shares were down 16% following its fiscal Q2 results.

Methode Electronics (MEI) stock was 14% lower after the company posted a wider-than-expected fiscal Q1 adjusted loss late Wednesday.

Advasa (ADBT) shares were down 12% after a more than 53% fall at the previous close when the company said it added USDC (USDC-USD) payments to its Visa card.